Fatma Avşar
Research Subjects
Research Interests
Fatma Avşar has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Aksel Siva
Cerrahpasa School of Medicine, Istanbul University, Turkey
1 shared publication - Ali Özhan Sıvacı
Department of Neurology, University of Health Sciences, Bursa Yüksek Ihtisas Training and Research Hospital, Bursa, Türkiye
1 shared publication - Ayse Sagduyu
Department of Neurology, Acıbadem University Medical Faculty, Istanbul, Turkey
1 shared publication - Bilge Piri Çınar
Department of Neurology, Faculty of Medicine, Samsun University, Samsun, Turkey
1 shared publication - Cihat Uzunkopru
Department of Neurology, Katip Celebi University School of Medicine, Izmir, Turkey
1 shared publication - Gulsen Akman Demir
Department of Neurology, İstanbul Bezmialem University Medical Faculty, Istanbul, Turkey
1 shared publication
Latest Publications
- 19 February 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (6) , 2737-2746
Treatment Adherence in a Large Cohort of Turkish Multiple Sclerosis Population
Objectives This study aimed to evaluate adherence to disease-modifying therapies (DMTs) among patients with multiple sclerosis (MS) and to identify factors influencing compliance, based on perceptions and preferences of both patients and neurologists. Methods Questionnaires were designed by a team of experts, including MS specialists, psychologists, and statisticians, to capture data on treatment adherence and related factors. A total of 1021 MS patients and their neurologists participated. Patients' adherence to oral, injectable, and infusion DMTs was assessed alongside demographic and disease-related characteristics. Results The study included 1021 MS patients with a mean age of 35.69 ± 9.07 years. Infusion therapies demonstrated the highest adherence rates (96.6%). Among all patients, 78.9% maintained treatment without interruption, while 56.7% of those who interrupted therapy informed their physicians. Patients with a disease duration of less than one year or more than 10 years exhibited lower rates of treatment interruption compared to those with a disease duration of 1–10 years (p = 0.032). In the injectable DMT group, significant differences in adherence were noted (p < 0.001). The lowest interruption rate (13.5%) was seen in patients with a disease duration of less than one year, whereas interruption rates were markedly higher (83%) in those with a duration exceeding 16 years. Conclusion Improving adherence requires a patient-centered, collaborative approach emphasizing shared decision-making between physicians and patients. Addressing factors that contribute to non-compliance is essential for optimizing treatment outcomes and enhancing long-term disease management in MS.
- 19 February 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (6) , 2737-2746
Treatment Adherence in a Large Cohort of Turkish Multiple Sclerosis Population
Objectives This study aimed to evaluate adherence to disease-modifying therapies (DMTs) among patients with multiple sclerosis (MS) and to identify factors influencing compliance, based on perceptions and preferences of both patients and neurologists. Methods Questionnaires were designed by a team of experts, including MS specialists, psychologists, and statisticians, to capture data on treatment adherence and related factors. A total of 1021 MS patients and their neurologists participated. Patients' adherence to oral, injectable, and infusion DMTs was assessed alongside demographic and disease-related characteristics. Results The study included 1021 MS patients with a mean age of 35.69 ± 9.07 years. Infusion therapies demonstrated the highest adherence rates (96.6%). Among all patients, 78.9% maintained treatment without interruption, while 56.7% of those who interrupted therapy informed their physicians. Patients with a disease duration of less than one year or more than 10 years exhibited lower rates of treatment interruption compared to those with a disease duration of 1–10 years (p = 0.032). In the injectable DMT group, significant differences in adherence were noted (p < 0.001). The lowest interruption rate (13.5%) was seen in patients with a disease duration of less than one year, whereas interruption rates were markedly higher (83%) in those with a duration exceeding 16 years. Conclusion Improving adherence requires a patient-centered, collaborative approach emphasizing shared decision-making between physicians and patients. Addressing factors that contribute to non-compliance is essential for optimizing treatment outcomes and enhancing long-term disease management in MS.